Literature DB >> 7797598

The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.

W Verbeek1, K Vehmeyer, B Wörmann, W Hiddemann.   

Abstract

An inherent defect of erythroid differentiation at the colony-forming unit blast (CFU-blast) compartment and (or) an impaired response of early erythroid progenitors (BFU-E) to growth stimulation are both considered to contribute to anemia in myelodysplastic syndromes (MDS). With the intention of improving survival and growth of early erythroid progenitors we investigated the effect of stem-cell factor (SCF) and interleukin-3 (IL-3) alone and in combination with erythropoietin, on the in vitro erythropoiesis of 13 patients with MDS and of three normal controls. SCF and IL-3 alone did not promote erythroid colony growth in MDS, while 3 cases responded to erythropoietin alone. In each of these, BFU-E colony growth could be increased by SCF, which was also found in all normal bone marrows. Altogether 6 cases showed a significant enhancement of BFU-E colony numbers by the combination of SCF and erythropoietin as compared to erythropoietin alone (P = 0.036). Out of the 6 responding cases, 5 belonged to the FAB-classified subgroups refractory anemia (RA) and refractory anemia with ringed sideroblasts (RA/RS) (5/5), while 1 patient was classified as having refractory anemia with excess of blasts (RAEB) (1/4). No patient with refractory anemia with excess of blasts in transformation (RAEB-T) (0/4) responded. In spite of these positive effects, the absolute number of BFU-E colonies remained reduced in all MDS cases when compared to normal controls. IL-3 proved ineffective in increasing the response to erythropoietin in MDS although it increased erythropoietin-induced BFU-E formation in normal controls significantly. We conclude that the striking synergistic effect of SCF and erythropoietin on erythroid colony formation seen with normal bone marrow is conserved in most cases with RA and RA/RS. In RAEB and RAEB-T the intrinsic defect of the erythroid differentiation pathway cannot be overcome by SCF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797598     DOI: 10.1007/bf01225685

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

1.  In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.

Authors:  S Merchav; O J Nielsen; H Rosenbaum; R Sharon; B Brenner; I Tatarsky; P Scigalla; L Wieczorek
Journal:  Leukemia       Date:  1990-11       Impact factor: 11.528

2.  Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium.

Authors:  K M Zsebo; J Wypych; I K McNiece; H S Lu; K A Smith; S B Karkare; R K Sachdev; V N Yuschenkoff; N C Birkett; L R Williams
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

3.  Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.

Authors:  R Kurzrock; M Talpaz; Z Estrov; M G Rosenblum; J U Gutterman
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

4.  Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile.

Authors:  T Papayannopoulou; M Brice; V C Broudy; K M Zsebo
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

5.  Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor.

Authors:  I D Bernstein; R G Andrews; K M Zsebo
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

6.  Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors.

Authors:  S Merchav; G Wagemaker; L M Souza; I Tatarsky
Journal:  Leukemia       Date:  1991-04       Impact factor: 11.528

7.  Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages.

Authors:  I K McNiece; K E Langley; K M Zsebo
Journal:  Exp Hematol       Date:  1991-03       Impact factor: 3.084

8.  Effect of stem cell factor on in vitro erythropoiesis in patients with bone marrow failure syndromes.

Authors:  B P Alter; M E Knobloch; L He; A P Gillio; R J O'Reilly; L K Reilly; R S Weinberg
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

9.  Erythroid burst formation in cultures of bone marrow and peripheral blood from patients with refractory anemia.

Authors:  D Amato; N R Khan
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

10.  Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.

Authors:  A Ganser; G Seipelt; A Lindemann; O G Ottmann; S Falk; M Eder; F Herrmann; R Becher; K Höffken; T Büchner
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.